Literature DB >> 12483759

Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?

Anthony O'Hagan1, John W Stevens.   

Abstract

This article addresses and challenges some common perceptions in the statistical assessment of costs and cost-effectiveness in health economics. Cost data typically exhibit highly skew distributions. Two techniques whose validity does not depend on any specific form of underlying distribution are the bootstrap and methods based on asymptotic normality of sample means. These methods are generally thought to be appropriate for the analysis of cost data. We argue that, even when these methods are technically valid, they may often lead to inefficient and even misleading inferences. It is important to apply methods that recognise the skewness in cost data. We further demonstrate that it may also be important to incorporate relevant prior information in a Bayesian analysis. Copyright 2002 John Wiley & Sons, Ltd.

Mesh:

Year:  2003        PMID: 12483759     DOI: 10.1002/hec.699

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  17 in total

1.  Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results.

Authors:  Theodoros Mantopoulos; Paul M Mitchell; Nicky J Welton; Richard McManus; Lazaros Andronis
Journal:  Eur J Health Econ       Date:  2015-10-07

2.  Identifying and accommodating statistical outliers when setting prospective payment rates for inpatient rehabilitation facilities.

Authors:  Susan M Paddock; Barbara O Wynn; Grace M Carter; Melinda Beeuwkes Buntin
Journal:  Health Serv Res       Date:  2004-12       Impact factor: 3.402

Review 3.  Economic evaluations: a new avenue of outcome assessment in spinal disorders.

Authors:  Nicole van der Roer; Norbert Boos; Maurits W van Tulder
Journal:  Eur Spine J       Date:  2005-12-01       Impact factor: 3.134

4.  Determinants of health expenditure growth of the OECD countries: jackknife resampling plan estimates.

Authors:  Albert A Okunade; Mustafa C Karakus; Charles Okeke
Journal:  Health Care Manag Sci       Date:  2004-08

5.  Immediate computed tomography or admission for observation after mild head injury: cost comparison in randomised controlled trial.

Authors:  Anders Norlund; Lars-Ake Marké; Jean-Luc af Geijerstam; Sven Oredsson; Mona Britton
Journal:  BMJ       Date:  2006-08-08

6.  Health care costs and their predictors of inflammatory bowel diseases in Germany.

Authors:  Anne Prenzler; Bernd Bokemeyer; J-Matthias von der Schulenburg; Thomas Mittendorf
Journal:  Eur J Health Econ       Date:  2010-10-22

7.  The cost of inpatient management of heart failure patients: a microcosting study in the Irish healthcare setting.

Authors:  R B Morgan; L McCullagh; M Barry; C Daly
Journal:  Ir J Med Sci       Date:  2016-11-19       Impact factor: 1.568

8.  The incremental costs of recommended therapy versus real world therapy in type 2 diabetes patients.

Authors:  C Crivera; D C Suh; E S Huang; E Cagliero; R W Grant; L Vo; H C Shin; J B Meigs
Journal:  Curr Med Res Opin       Date:  2006-11       Impact factor: 2.580

9.  Costing and cost analysis in randomized controlled trials: caveat emptor.

Authors:  Daniel Polsky; Henry Glick
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

10.  Cost-effectiveness of an integrated 'fast track' rehabilitation service for multi-trauma patients involving dedicated early rehabilitation intervention programs: design of a prospective, multi-centre, non-randomised clinical trial.

Authors:  Sevginur Kosar; Henk Am Seelen; Bena Hemmen; Silvia Maa Evers; Peter Rg Brink
Journal:  J Trauma Manag Outcomes       Date:  2009-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.